HanchorBio Expands Global Growth Strategy With Taiwan Listing and HCB101 Clinical Progress
TAIPEI, Taiwan, SHANGHAI, China and SAN FRANCISCO, California — May 28, 2026 HanchorBio, Inc. announced that the company will...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
TAIPEI, Taiwan, SHANGHAI, China and SAN FRANCISCO, California — May 28, 2026 HanchorBio, Inc. announced that the company will...
SAN FRANCISCO and BOSTON, May 27, 2026 Apogee Therapeutics announced a landmark $1.3 billion strategic financing collaboration with Blackstone...
LOS ANGELES, USA | March 24, 2026 Turn Therapeutics, Inc., a clinical-stage dermatology-focused biotechnology company, has announced a strategic...
ZURICH, Switzerland – February 27, 2026 Veraxa Biotech AG announced that its shareholders have approved the previously disclosed business...
JUPITER, Fla., Feb. 23, 2026 — Jupiter Neurosciences, a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system...
MIRAMAR, FLORIDA, UNITED STATES — February 17, 2026 HCW Biologics announced the pricing of a $1.5 million follow-on public...
SAN FRANCISCO, Feb. 13, 2026 — Nektar Therapeutics announced the successful closing of a $460 million underwritten public offering,...
NEW HAVEN, Conn., Feb. 5, 2026 — Veradermics, Incorporated, a late clinical-stage biopharmaceutical company focused on dermatology therapeutics, announced...
SOUTH SAN FRANCISCO, CALIFORNIA | January 27, 2026 — TRexBio, Inc., a clinical-stage biotechnology company focused on precision immunoregulatory...
KING OF PRUSSIA, PENNSYLVANIA | January 26, 2026 — Phio Pharmaceuticals has announced its participation in the Third Annual...
